Karuna Therapeutics Reports First Quarter 2021 Financial Results and Provides General Business Update

KarXT is currently being evaluated as a potential treatment for psychiatric disorders, including schizophrenia and dementia-related psychosis.\nKarXT for the treatment of psychosis in adults with schizophrenia.